Alnylam Pharmaceuticals | ALNY - Cost Of Sales

Stock Price
329.84
Daily Change
-1.40 -0.42%
Monthly
-7.02%
Yearly
39.11%
Q1 Forecast
325.77

Alnylam Pharmaceuticals reported $267.72M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Moderna USD 452M 245M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 216M Sep/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025